Epithelioid Inflammatory Myofibroblastic Sarcoma Responsive to Surgery and an ALK Inhibitor in a Patient with Panhypopituitarism

Kotomi Kurihara-Hosokawa; Isao Kawasaki; Anna Tamai; Yoko Yoshida; Yosuke Yakushiji; Hiroki Ueno; Mariko Fukumoto; Hiroko Fukushima; Takeshi Inoue; Masayuki Hosoi

doi:10.2169/internalmedicine.53.2546

CASE REPORTS

Epithelioid Inflammatory Myofibroblastic Sarcoma Responsive to Surgery and an ALK Inhibitor in a Patient with Panhypopituitarism

Kotomi Kurihara-Hosokawa, Isao Kawasaki, Anna Tamai, Yoko Yoshida, Yosuke Yakushiji, Hiroki Ueno, Mariko Fukumoto, Hiroko Fukushima, Takeshi Inoue, Masayuki Hosoi

著者情報

キーワード: epithelioid inflammatory myofibroblastic sarcoma (EIMS), RANBP2-ALK fusion gene, ALK inhibitor, inflammatory myofibroblastic tumor (IMT)

ジャーナルオープンアクセス

2014 年 53 巻 19 号 p. 2211-2214

DOI https://doi.org/10.2169/internalmedicine.53.2546

詳細

抄録

We encountered a case of epithelioid inflammatory myofibroblastic sarcoma (EIMS) originating from an abdominal organ that rapidly regrew twice. The patient underwent two surgeries. Large tumors grew within three months after the second surgery. The patient subsequently received chemotherapy with an anaplastic lymphoma kinase (ALK) inhibitor. Although EIMS has a poor prognosis, the patient continues to be alive with disease 14 months after surgical treatment and the administration of the ALK inhibitor.

責任著者(Corresponding author)

J-STAGEへの登録はこちら（無料）